Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over 5 years of experience in covering biotech and healthcare, having prepared detailed reports on more than 1,000 companies [1]

Group 1 - The article discusses the performance of Kymera Therapeutics (NASDAQ: KYMR), noting a significant decline in stock price from $46 to $31, representing a 33% drop, after reaching a high of over $50 in November 2024 [1] - The investing group Haggerston BioHealth provides insights into the biotech, pharma, and healthcare sectors, offering catalysts, buy and sell ratings, and detailed financial analyses for major pharmaceutical companies [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled extensive reports on more than 1,000 companies in the sector [1]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, inte ...

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, and has prepared detailed reports on more than 1,000 companies [1]

Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [2]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Insights - The overall holding ratio of the pharmaceutical sector by funds has been continuously declining, with non-pharmaceutical active funds underweighting pharmaceuticals again since the first half of 2022 [9][11] - The holding ratio of all public funds in the pharmaceutical sector for the second half of 2024 is 9.6%, a decrease of 1.2 percentage points from the previous period [3][11] - The holding ratio of all active public funds in the pharmaceutical sector is 9.9%, also down by 1.2 percentage points [3][11] - Non-pharmaceutical funds have a holding ratio of 6.0%, down by 0.8 percentage points, with an increased underweight ratio of 0.26% [3][11] Fund Holdings Overview - The holding ratios for different segments within the pharmaceutical industry show varied trends, with Pharma and Bio-Tech seeing increases, while generic drugs and traditional Chinese medicine are declining [5][15] - The top three segments with increased holdings among all public funds are CXO (+3.8%), Pharma (+2.7%), and Biotech (+0.8%) [8][11] - The top three segments with decreased holdings are medical devices (-1.9%), traditional Chinese medicine (-1.9%), and blood products (-1.3%) [8][11] Detailed Fund Type Analysis - Active pharmaceutical funds are overweight in Pharma, Biotech, and CXO, while non-pharmaceutical funds are overweight in Pharma, CXO, and medical devices [8][11] - The total market value of holdings for all public funds in the pharmaceutical sector is led by 恒瑞医药 (CNY 47.7 billion), 迈瑞医疗 (CNY 45.9 billion), and 药明康德 (CNY 37.2 billion) [8][11] - The top five stocks with increased holdings include 药明康德 (+CNY 7.5 billion) and 联影医疗 (+CNY 3.7 billion) [8][11]